These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25667925)

  • 1. Receptor binding domain based HIV vaccines.
    Liu H; Bi W; Wang Q; Lu L; Jiang S
    Biomed Res Int; 2015; 2015():594109. PubMed ID: 25667925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].
    Vzorov AN; Compans RW
    Mol Biol (Mosk); 2016; 50(3):406-15. PubMed ID: 27414779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 9. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    Yang X; Tomov V; Kurteva S; Wang L; Ren X; Gorny MK; Zolla-Pazner S; Sodroski J
    J Virol; 2004 Dec; 78(23):12975-86. PubMed ID: 15542649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INFECTIOUS DISEASES. Designer proteins produce potent HIV defense.
    Cohen J
    Science; 2015 Jun; 348(6241):1297. PubMed ID: 26089490
    [No Abstract]   [Full Text] [Related]  

  • 12. An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.
    Yu HT; Tian D; Wang JY; Guo CX; Li Y; Wang X; Li D; Zhang FM; Zhuang M; Ling H
    PLoS One; 2014; 9(12):e115047. PubMed ID: 25546013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 16. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.
    Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM
    AIDS Res Hum Retroviruses; 2003 Oct; 19(10):891-900. PubMed ID: 14585221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of HIV vaccines].
    Shibata R
    Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".
    Wang Z; Wang SX; Liu SY; Bao ZY; Zhuang DM; Li L; Zhang CH; Zhang L; Li JY; Lu S
    Chin Med J (Engl); 2009 Oct; 122(19):2339-45. PubMed ID: 20079137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.